Type‐1 inhibitor of plasminogen activators
- 16 December 1991
- journal article
- Published by Wiley in FEBS Letters
- Vol. 295 (1-3) , 102-106
- https://doi.org/10.1016/0014-5793(91)81395-o
Abstract
Type-1 inhibitor of plasminogen activators (PAI-I) occurs in purified preparations in a latent form that can be activated with denaturants; in vivo, latency is prevented by binding to vitronectin. We have compared latent, denaturant-activated and reactive centre-cleaved human PAI-1 with respect to thermal stability and affinity to monoclonal antibodies. By both criteria, latent and cleaved PAI-1 are very similar or indistinguishable, and clearly different from active PAI-1. Our findings suggest that the conformations of latent and reactive centre-cleaved PAI-1 are similar and resemble the so-called relaxed (R) serpin conformation, while that of active PAI-1 is different and resembles the stressed S serpin conformationKeywords
This publication has 26 references indexed in Scilit:
- Crystal structure of cleaved human α1-antichymotrypsin at 2.7 å resolution and its comparison with other serpinsJournal of Molecular Biology, 1991
- Crystal structure of plakalbumin, a proteolytically nicked form of ovalbuminJournal of Molecular Biology, 1990
- Plasminogen activator inhibitors: hormonally regulated serpinsMolecular and Cellular Endocrinology, 1990
- Plasminogen activator inhibitor 1 (PAI) is bound to vitronectin in plasmaFEBS Letters, 1988
- Properties of thrombin- and elastase-modified human antithrombin IIIBiochemistry, 1988
- Bovine plasminogen activator inhibitor 1: Specificity determinations and comparison of the active, latent, and guanidine-activated formsBiochemistry, 1988
- Plasminogen activator inhibitor type‐1 : reactive center and amino‐terminal heterogeneity determined by protein and cDNA sequencingFEBS Letters, 1986
- Enzyme-Linked Immunosorbent Assay for Human Urokinase-Type Plasminogen Activator and its Proenzyme Using a Combination of Monoclonal and Polyclonal AntibodiesJournal of Immunoassay, 1986
- Plasminogen activators catalyse conversion of inhibitor from fibrosarcoma cells to an inactive form with a lower apparent molecular massFEBS Letters, 1986
- Plakalbumin, α1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosisNature, 1985